Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
about
(-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.The Pharmacological Basis of Cannabis Therapy for Epilepsy.Medical Marijuana: Just the Beginning of a Long, Strange Trip?Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.
P2860
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
@ast
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
@en
type
label
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
@ast
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
@en
prefLabel
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
@ast
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
@en
P2860
P1433
P1476
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.
@en
P2093
William G Notcutt
P2860
P2888
P304
P356
10.1007/S13311-015-0383-5
P577
2015-08-20T00:00:00Z